Share This

Public company info - Luye Pharma Group Ltd. , 02186.HK

Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Luye Pharma Group Ltd., 02186.HK - Company Profile
Chairman LIU Dian Bo
Share Issued (share) 3,541,000,000
Par Currency U.S. Dollar
Par Value 0.02
Industry Medicine
Corporate Profile Business Summary: The group is principally engaged in the development, production, marketing and sale of pharmaceutical products. Performance for the year: For the year ended 31 December 2019, the Group’s revenue amounted to approximately RMB6,357.6 million, as compared to RMB5,173.4 million for the year ended 31 December 2018, representing an increase of approximately RMB1,184.2 million, or 22.9%. For the year ended 31 December 2019, the Group’s gross profit increased to RMB4,878.9 million, as compared to RMB4,049.4 million for the year ended 31 December 2018, representing an increase of approximately RMB829.5 million, or 20.5%. The gross profit margin of 76.7%. Business Review: In 2019, the Company promoted transformation and high-quality development by centering on strategic areas such as innovative R&D, marketing, mergers and acquisitions and cooperation, and achieved satisfactory performance returns. In 2019, the sales revenue of the Company amounted to RMB6.358 billion, representing a year-on-year increase of 22.9%; EBITDA reached RMB2.488 billion, representing a year-on-year increase of 26.9%; and normalised net profit attributable to shareholders amounted to RMB1.592 billion, representing a year-on-year increase of 19.4%. In terms of R&D, the Company has a rich reserve of product candidates in the world, and the layout of antibody biological pipelines is also in its infancy. Among the Group’s self-developed small molecule/new preparations of new drugs under research: the innovative preparation LY03004 has entered the new drug application (NDA) stage in both China and the U.S., and also obtained the priority review status in China; the NDA declaration for the innovative small molecule drug LY03005 has also been accepted in the U.S.; another 2 new drug projects have commenced Phase III clinical trial in Europe and the U.S., 5 new drug projects have commenced Phase III clinical trial in China; and 3 new drug projects have applied for NDA in China. In addition, the Company has a solid layout in the field of antibody biopharmaceuticals, which leads to the formation of a complete industrial chain layout from R&D, production to commercialisation promptly For marketing, all core products have grown steadily, and the commercial layout centering on CNS is also advancing rapidly. Among the core products: Lipusu®, Xuezhikang®, Bei Xi®, Maitongna® and Seroquel® continued to grow by double digits, and another two exclusive products of CMNa® and Okai® have strong sales and are expected to become the new batch of the Company’s largest single product with sales of over RMB100 million. In addition, as a strategic area that the Company focuses on, the global business integration for Seroquel® is being carried out efficiently. The Company has established a CNS team comprising over 100 employees in China to take over the distribution or promotion business of Seroquel® products in more than 10 countries and regions overseas, and has set up its own self-operated sales team in some overseas regions to vigorously expand the domestic and foreign markets of the products, and lay a solid foundation for the commercial operation of subsequent products in the CNS field. The Company insists on the parallel development of both endogeny and extension, and strategically promotes the innovation, transformation and upgrading of the Company leveraging on external resources so as to enhance its market competitiveness. Following the smooth development of cooperation in Mainland China, the strategic cooperation between the Company and AstraZeneca has been continuously deepened to jointly promote the domestic and international process of Xuezhikang® Capsules. The Company introduced the innovative oncology drug Zepsyre® (Lurbinectedin) from PharmaMar, and has acquired the exclusive rights to develop and commercialise the drug in China. Zepsyre® has entered the NDA stage and obtained the priority review status in the U.S.. In addition, the Company has completed the acquisition of Shandong Boan, and acquired a series of assets such as all pipeline portfolio, antibody screening platform, intellectual property rights and antibody production platform, thus laying a more solid foundation for the in-depth layout of the biopharmaceutical field. Prospects: For Luye Pharma, 2020 will be a year of both opportunities and challenges. The Company will actively carry out a series of reform initiatives to adapt to the changing environment, improve operational and management efficiency, continuously increase the market share of existing products, and strive to launch a number of new drugs in the international market as soon as possible. The Group are confident that, leveraging on the Company’s competitive advantage in innovative products, extensive pipeline portfolio, global supply chain system and business operation strength, as well as precise M&A and collaboration capabilities, the Group have the capability to effectively ensure that the Group’s Company will continue to maintain a highquality and healthy growth in the future.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.